{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:21:46Z","timestamp":1790011306792,"version":"4.0.1"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["57715"],"award-info":[{"award-number":["57715"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,11,17]]},"abstract":"<jats:p>Combination therapy may enhance imipenem\/cilastatin\/relebactam\u2019s (I\/R) activity against<jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>and suppress resistance development. Human-simulated unbound plasma concentrations of I\/R at 1.25 g every 6 h (h), colistin at 360\u2009mg daily, and amikacin at 25\u2009mg\/kg daily were reproduced alone and in combination against six imipenem-nonsusceptible<jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>isolates in an<jats:italic>in vitro<\/jats:italic>pharmacodynamic model over 24\u2009h.<\/jats:p>","DOI":"10.1128\/aac.01764-20","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T14:54:36Z","timestamp":1603896876000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Imipenem\/Cilastatin\/Relebactam Alone and in Combination against<i>Pseudomonas aeruginosa<\/i>in the<i>In Vitro<\/i>Pharmacodynamic Model"],"prefix":"10.1128","volume":"64","author":[{"given":"Iris H.","family":"Chen","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-0165","authenticated-orcid":false,"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-3126","authenticated-orcid":false,"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.008"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.022"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.07.002"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S169271"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.10.028"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"28","author":"Horcajada JP","year":"2019","unstructured":"Horcajada JP, Montero M, Oliver A, Sorl\u00ed L, Luque S, G\u00f3mez-Zorrilla S, Benito N, Grau S. 2019. Epidemiology and treatment of multidrug resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 28:e00031-19.","journal-title":"Clin Microbiol Rev"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.04.012"},{"key":"e_1_3_3_9_2","volume-title":"Recarbrio (imipenem, cilastatin, and relebactam) prescribing information","author":"Merck & Co","year":"2020","unstructured":"Merck & Co. 2020. Recarbrio (imipenem, cilastatin, and relebactam) prescribing information. Merck & Co., Inc., Whitehouse Station, NJ,"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.001"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00535-19"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir934"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1477"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00997-19"},{"key":"e_1_3_3_17_2","unstructured":"FDA. Imipenem-cilastatin-relebactam injection FDA identified breakpoints. 2020. U.S. Food and Drug Administration Bethesda MD. https:\/\/www.fda.gov\/drugs\/development-resources\/imipenem-cilastatin-relebactam-injection. Accessed 14 February 2020."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz824"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02323-17"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.08.026"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-16"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05927-11"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03706-14"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02384-17"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00903-09"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ964"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2193"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.004"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2778"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1755"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz552"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00779-19"},{"key":"e_1_3_3_35_2","volume-title":"M100 performance standards for antimicrobial susceptibility testing, 30th ed","author":"CLSI","year":"2020","unstructured":"CLSI. 2020. M100 performance standards for antimicrobial susceptibility testing, 30th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00280-18"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01411-17"},{"key":"e_1_3_3_38_2","first-page":"285","article-title":"Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients","volume":"17","author":"Mahmoudi L","year":"2013","unstructured":"Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. 2013. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 17:285\u2013291.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01624-13"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.019"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01764-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01764-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:39:20Z","timestamp":1669354760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01764-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,11,17]]}},"alternative-id":["10.1128\/AAC.01764-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01764-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"2020-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01764-20"}}